[HTML][HTML] Healthcare-associated urinary tract infections in urology

J Medina-Polo, KG Naber… - GMS infectious diseases, 2021 - ncbi.nlm.nih.gov
The purpose of the present review is to report the incidence and characteristics of healthcare-
associated urinary tract infections (HAUTIs) in urology with their microbiological and …

Clinical cure rate and cost-effectiveness of carbapenem-sparing beta-lactams vs. meropenem for Gram-negative infections: A systematic review, meta-analysis, and …

CP Nguyen, TND Do, R Bruggemann… - International journal of …, 2019 - Elsevier
The increasing incidence of infections caused by extended-spectrum beta-lactamase
(ESBL)/AmpC-producing bacteria leads to increasing use of carbapenems and risk of …

OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli

DM Livermore, M Day, P Cleary… - Journal of …, 2019 - academic.oup.com
Background ESBL-producing Escherichia coli have expanded globally since the turn of the
century and present a major public health issue. Their in vitro susceptibility to …

Resistance mechanisms and population structure of highly drug resistant Klebsiella in Pakistan during the introduction of the carbapenemase NDM-1

E Heinz, H Ejaz, J Bartholdson Scott, N Wang… - Scientific reports, 2019 - nature.com
Klebsiella pneumoniae is a major threat to public health with the emergence of isolates
resistant to most, if not all, useful antibiotics. We present an in-depth analysis of 178 …

Which non-carbapenem antibiotics are active against extended-spectrum β-lactamase-producing Enterobacteriaceae?

H Bouxom, D Fournier, K Bouiller, D Hocquet… - International journal of …, 2018 - Elsevier
In this study, the activity of 18 non-carbapenem antibiotics was evaluated against 100
extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (ESBL-Ec) and 50 ESBL …

Carbapenem-sparing therapy for extended-spectrum β-lactamase–producing E coli and Klebsiella pneumoniae bloodstream infection: the search continues

MK Hayden, SY Won - Jama, 2018 - jamanetwork.com
Bloodstream infections due to Escherichia coli and Klebsiella pneumoniae are associated
with significant morbidity, mortality, and financial costs. 1 Resistance to third-generation …

Pragmatic comparison of piperacillin/tazobactam versus carbapenems in treating patients with nosocomial pneumonia caused by extended-spectrum β-lactamase …

L Zha, X Li, Z Ren, D Zhang, Y Zou, L Pan, S Li, S Chen… - Antibiotics, 2022 - mdpi.com
The effectiveness of piperacillin/tazobactam for managing nosocomial pneumonia caused
by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae is unknown. To …

Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: challenges, implications and surveillance strategy for India

B Veeraraghavan, AK Pragasam… - Indian Journal of …, 2018 - Elsevier
Antimicrobial resistance (AMR) is a major public health concern across the globe, and it is
increasing at an alarming rate. Multiple classes of antimicrobials have been used for the …

[HTML][HTML] Do weekly surveillance cultures contribute to antibiotic stewardship and correlate with outcome of HSCT in children? A multicenter real-world experience of 5 …

R Dhanya, RK Agarwal, S Ramprakash… - … and Cellular Therapy, 2022 - Elsevier
The utility of weekly rectal swab surveillance cultures (RSSCs) as a resource to identify gut
colonization with extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli or …

Efficacy of carbapenem vs non carbapenem β-lactam therapy as empiric antimicrobial therapy in patients with extended-spectrum β-lactamase-producing …

E Cariou, R Griffier, A Orieux, S Silva, S Faguer… - Annals of Intensive …, 2023 - Springer
Background The rise in antimicrobial resistance is a global threat responsible for about
33,000 deaths in 2015 with a particular concern for extended-spectrum beta-lactamase …